Under consent: participation of people with HIV in an Ebola vaccine trial in Canada
- PMID: 33836725
- PMCID: PMC8033276
- DOI: 10.1186/s12910-021-00606-6
Under consent: participation of people with HIV in an Ebola vaccine trial in Canada
Erratum in
-
Correction to: Under consent: participation of people with HIV in an Ebola vaccine trial in Canada.BMC Med Ethics. 2021 Jun 1;22(1):69. doi: 10.1186/s12910-021-00629-z. BMC Med Ethics. 2021. PMID: 34074298 Free PMC article. No abstract available.
Abstract
Background: Little is known about volunteers from Northern research settings who participate in vaccine trials of highly infectious diseases with no approved treatments. This article explores the motivations of HIV immunocompromised study participants in Canada who volunteered in a Phase II clinical trial that evaluated the safety and immunogenicity of an Ebola vaccine candidate.
Methods: Observation at the clinical study site and semi-structured interviews employing situational and discursive analysis were conducted with clinical trial participants and staff over one year. Interviews were recorded, transcribed and analysed using critical qualitative interpretivist thematic analytical techniques. Patterns were identified, clustered and sorted to generate distinct and comprehensive themes. We then reassembled events and contexts from the study participants' stories to develop two ideal portraits based on "composite characters" based on study participants features. These provide ethnographically rich details of participants' meaningful social worlds while protecting individual identities.
Results: Ten of the 14 clinical trial participants, and 3 study staff were interviewed. Participant demographics and socio-economic profiles expressed limited contextual diversity. Half were men who have sex with men, half were former injection drug users experiencing homelessness, one was female, none were racialized minorities and there were no people from HIV endemic countries. Fully 90% had previous involvement in other clinical studies. Their stories point to particular socio-economic situations that motivated their participation as clinical labor through trial participation.
Conclusions: Our findings support Fisher's argument of "structural coercion" in clinical trial recruitment of vulnerable individuals experiencing precarious living conditions. Clinical trials should provide more detail of the structural socio-economic conditions and healthcare needs which lie "under consent" of study participants. Going well beyond an overly convenient narrative of altruism, ethical deliberation frameworks need to sufficiently address the structural conditions of clinical trials. We offer concrete possibilities for this and acknowledge that further research and clinical data should be made available underlying study participant contexts with regards to recruitment and participation in resource poor settings, in both the South and the North.
Conflict of interest statement
None.
Similar articles
-
Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.Vaccine. 2019 Jan 7;37(2):289-295. doi: 10.1016/j.vaccine.2018.11.014. Epub 2018 Dec 7. Vaccine. 2019. PMID: 30528592
-
Factors influencing participation in an Ebola vaccine trial among front-line workers in Guinea.Vaccine. 2019 Nov 15;37(48):7165-7170. doi: 10.1016/j.vaccine.2019.09.094. Epub 2019 Oct 14. Vaccine. 2019. PMID: 31623917
-
Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial.Lancet Infect Dis. 2020 Apr;20(4):455-466. doi: 10.1016/S1473-3099(19)30614-0. Epub 2020 Jan 14. Lancet Infect Dis. 2020. PMID: 31952923 Clinical Trial.
-
Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context.Trials. 2019 Jul 11;20(1):422. doi: 10.1186/s13063-019-3487-0. Trials. 2019. PMID: 31296253 Free PMC article. Review.
-
Ebola vaccines in clinical trial: The promising candidates.Hum Vaccin Immunother. 2017 Jan 2;13(1):153-168. doi: 10.1080/21645515.2016.1225637. Epub 2016 Oct 20. Hum Vaccin Immunother. 2017. PMID: 27764560 Free PMC article. Review.
Cited by
-
Correction to: Under consent: participation of people with HIV in an Ebola vaccine trial in Canada.BMC Med Ethics. 2021 Jun 1;22(1):69. doi: 10.1186/s12910-021-00629-z. BMC Med Ethics. 2021. PMID: 34074298 Free PMC article. No abstract available.
-
Factors that impact on recruitment to vaccine trials in the context of a pandemic or epidemic: a qualitative evidence synthesis.Cochrane Database Syst Rev. 2023 Sep 1;9(9):MR000065. doi: 10.1002/14651858.MR000065.pub2. Cochrane Database Syst Rev. 2023. PMID: 37655964 Free PMC article. Review.
References
-
- Petryna A. Ethical variability: drug development and globalizing clinical trials. Am Ethnol. 2005;32(2):183–197. doi: 10.1525/ae.2005.32.2.183. - DOI
-
- Abadie R. The professional guinea pig: big pharma and the risky world of human subjects. Durham: Duke University Press; 2010. p. 200.
-
- Cooper M, Waldby C. Clinical labor: tissue donors and research subjects in the global bioeconomy. Durham: Duke University Press; 2014. p. 296.
-
- Graham JE. Ebola vaccine innovation: a case study of pseudoscapes in global health. Crit Public Health. 2019;29(4):401–412. doi: 10.1080/09581596.2019.1597966. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical